| Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. | |
| | |
MedLine Citation:
|
PMID: 7682909 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Mifepristone is a potent oral antiprogestogen which acts at the level of the receptor, having a high affinity for the progesterone receptor. Most of the clinical trials have studied its efficacy in the termination of early pregnancy when used in conjunction with a low dosage of a prostaglandin analogue. In these studies, mifepristone 100 to 600mg administered as a single dose or over 3 or 4 days, 36 to 48 hours before a prostaglandin analogue given vaginally, intramuscularly or orally, induced complete abortion in about 95% of women. Used alone, mifepristone is an effective cervical priming agent prior to termination of first trimester pregnancy by vacuum aspiration, and facilitates termination of second trimester pregnancy by prostaglandin by reducing the interval between the start of prostaglandin treatment and termination, the cumulative prostaglandin dosage, and the adverse effects associated with these drugs. Mifepristone can also be used to induce labour in cases of intrauterine fetal death. Mifepristone has been shown to be an effective postcoital contraceptive with a likely emergency role, since its repeated use modifies the menstrual cycle. Pilot studies have been performed in unresectable meningioma and metastatic breast cancer, and in Cushing's syndrome. Mifepristone is generally well tolerated, and thus is an effective, appropriate, medical alternative to surgical termination of early pregnancy. It has as yet unexplored potential as a postcoital contraceptive and in oncology. |
| | |
Authors:
|
R N Brogden; K L Goa; D Faulds |
Related Documents
:
|
2976579 - Selective termination of multiple gestations. 14624219 - Misoprostol and pregnancy: ever-increasing indications of effective usage. 22115959 - The progesterone receptor regulates implantation, decidualization, and glandular develo... 20227549 - Two medical abortion regimens for late first-trimester termination of pregnancy: a pros... 17131609 - Exploration of the views of traditional healers regarding the termination of pregnancy ... 8030739 - Efficacy of second-trimester selective termination for fetal abnormalities: internation... 9822499 - Maternal serum thromboxane b2 concentrations do not predict improved outcomes in high-r... 9704769 - Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood... 9347279 - Pregnancy in patients with pulmonary autograft valve replacement. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drugs Volume: 45 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 1993 Mar |
Date Detail:
|
Created Date: 1993-05-26 Completed Date: 1993-05-26 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: NEW ZEALAND |
Other Details:
|
Languages: eng Pagination: 384-409 Citation Subset: IM |
Affiliation:
|
Adis International Limited, Auckland, New Zealand. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Contraceptives, Postcoital
/
pharmacokinetics,
pharmacology* Female Humans Mifepristone / adverse effects, pharmacokinetics, pharmacology*, therapeutic use Pregnancy |
| Chemical | |
Reg. No./Substance:
|
0/Contraceptives, Postcoital; 84371-65-3/Mifepristone |
| Comments/Corrections | |
Erratum In:
|
Drugs 1993 Aug;46(2):268 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Drug treatment of resistant schizophrenia. Limitations and recommendations.
Next Document: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential...